Michael Barbella, Managing Editor10.03.22
Subchondral Solutions Inc. has received additional U.S. Food and Drug Administration 501(k) clearance for its S-Core Implant Platform.
"The recent clearance, with expanded indications, will allow Subchondral Solutions to broaden our marketing efforts and messaging," CEO Thomas Kinder said. “Our S-Core device provides surgeons in foot and ankle, upper extremities and sports medicine options to best serve their patients.”
The company's platform is a delivery system for treating bone edema in the subchondral bone beneath the cartilage. The new clearance allows for S-Core to be used as an anchor to suture and attach soft tissue allografts to the implant. S-Core can now create a functional “time zero” repair to help restore biomechanical function. which could shorten the time to return to full activity. S-Core Implants are coated with hydroxyapatite to maximize bone and biologic healing.
Cleared by the FDA in 2020, the S-Core delivery platform is indicated for the fixation of small bone fragments, such as osteochondral fragments and cancellous fragments, appropriate for the size of the damage area which may include simple metaphyseal fractures; condylar fractures; osteochondritis dissecans; areas where accurate implant placement is vital; patellar fractures, navicular fractures, cancellous bone fragments; osteochondral fragments, intra-articular fractures and osteochondral fixation and fractures, and minimally invasive reconstruction of fractures and joints.
“The S-Core Implant Platform may be used as a stand-alone screw for the fixation of trabecular fractures, fusion, and osteotomies,” said Jordan Peana, Subchrondral’s vice president of sales. “The S-Core Implant System may also be used with our S-Fibre Suture when a suture anchor is needed for the attachment of soft tissue to bone."
S-Core can be used in any osteochondral fracture appropriate for the size of the device, including for the knee, elbow, hand, foot, ankle and shoulder.
Subchondral Solutions was formed in 2013 and aims to advance joint damage treatment by addressing the source of the problem with a biomechanical, efficient, cost-effective scalable system.
"The recent clearance, with expanded indications, will allow Subchondral Solutions to broaden our marketing efforts and messaging," CEO Thomas Kinder said. “Our S-Core device provides surgeons in foot and ankle, upper extremities and sports medicine options to best serve their patients.”
The company's platform is a delivery system for treating bone edema in the subchondral bone beneath the cartilage. The new clearance allows for S-Core to be used as an anchor to suture and attach soft tissue allografts to the implant. S-Core can now create a functional “time zero” repair to help restore biomechanical function. which could shorten the time to return to full activity. S-Core Implants are coated with hydroxyapatite to maximize bone and biologic healing.
Cleared by the FDA in 2020, the S-Core delivery platform is indicated for the fixation of small bone fragments, such as osteochondral fragments and cancellous fragments, appropriate for the size of the damage area which may include simple metaphyseal fractures; condylar fractures; osteochondritis dissecans; areas where accurate implant placement is vital; patellar fractures, navicular fractures, cancellous bone fragments; osteochondral fragments, intra-articular fractures and osteochondral fixation and fractures, and minimally invasive reconstruction of fractures and joints.
“The S-Core Implant Platform may be used as a stand-alone screw for the fixation of trabecular fractures, fusion, and osteotomies,” said Jordan Peana, Subchrondral’s vice president of sales. “The S-Core Implant System may also be used with our S-Fibre Suture when a suture anchor is needed for the attachment of soft tissue to bone."
S-Core can be used in any osteochondral fracture appropriate for the size of the device, including for the knee, elbow, hand, foot, ankle and shoulder.
Subchondral Solutions was formed in 2013 and aims to advance joint damage treatment by addressing the source of the problem with a biomechanical, efficient, cost-effective scalable system.